Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome

References

• Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet (London, England). 2014;383:2239–2252.
   PubMed Web of Science ®Google Scholar
• Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117:7121–7125.
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Ebert BL. Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol 2017;35:968–974.
   PubMed Web of Science ®Google Scholar
• Feng Y, Li X, Cassady K, et al. Tet2 function in hematopoietic malignancies, immune regulation, and DNA repair. Front Oncol. 2019;9:210. doi:10.3389/fonc.2019.00210.
   PubMed Web of Science ®Google Scholar
• Guillamot M, Cimmino L, Aifantis I. The impact of DNA methylation in hematopoietic malignancies. Trends Cancer. 2016;2:70–83.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–247.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–3627; quiz 99.
   PubMed Web of Science ®Google Scholar
• Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705–2712.
   PubMed Web of Science ®Google Scholar
• Hunter AM, Komrokji RS, Yun S, et al. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021;5:1017–1028.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. IPSS-R Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49:D605–D612.
   PubMed Web of Science ®Google Scholar
• Doncheva NT, Morris JH, Gorodkin J, et al. Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res 2019;18:623–632.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496–2506.
   PubMed Web of Science ®Google Scholar
• Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the revised international prognostic scoring system in treated patients with myelodysplastic syndromes. Leukemia. 2016;30:2214–2220.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Komrokji R, Vaupel C, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30:666–673.
   PubMed Web of Science ®Google Scholar
• Boultwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010;24:1062–1065.
   PubMed Web of Science ®Google Scholar
• Ito S, Shen L, Dai Q, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333:1300–1303.
   PubMed Web of Science ®Google Scholar
• Pronier E, Almire C, Mokrani H, et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood. 2011;118:2551–2555.
   PubMed Web of Science ®Google Scholar
• Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009;113:6403–6410.
   PubMed Web of Science ®Google Scholar
• Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930–935.
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E. Significance of JAK2 and TET2 mutations in myelodysplastic syndromes. Blood Rev 2010;24:83–90.
   PubMed Web of Science ®Google Scholar
• Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010;116:3923–3932.
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114:3285–3291.
   PubMed Web of Science ®Google Scholar
• Gangat N, Mudireddy M, Lasho TL, et al. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. Am J Hematol 2018;93:691–697.
   PubMed Web of Science ®Google Scholar
• Lin Y, Lin Z, Cheng K, et al. Prognostic role of TET2 deficiency in myelodysplastic syndromes: a meta-analysis. Oncotarget. 2017;8:43295–43305.
   PubMedGoogle Scholar
• Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12:599–612.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? Leukemia. 2011;25:1059–1063.
   PubMed Web of Science ®Google Scholar
• Issa J-P. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010;24:317–330.
   PubMed Web of Science ®Google Scholar
• Daw S, Chatterjee R, Law A, et al. Analysis of hematopathology and alteration of JAK1/STAT3/STAT5 signaling axis in experimental myelodysplastic syndrome. Chem Biol Interact. 2016;260:176–185.
   PubMed Web of Science ®Google Scholar
• Niimi H, Harada H, Harada Y, et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia. 2006;20:635–644.
   PubMed Web of Science ®Google Scholar
• He Q, Zheng Q, Xu F, et al. IGF-IR promotes clonal cell proliferation in myelodysplastic syndromes via inhibition of the MAPK pathway. Oncol Rep. 2020;44:1094–1104.
   PubMed Web of Science ®Google Scholar
• Padhi A, Nain AS. ECM in differentiation: a review of matrix structure, composition and mechanical properties. Ann Biomed Eng. 2020;48:1071–1089.
   PubMed Web of Science ®Google Scholar
• Aanei CM, Eloae FZ, Flandrin-Gresta P, et al. Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells. Exp Cell Res 2011;317:2616–2629.
   PubMed Web of Science ®Google Scholar
• Wang BG, Yi DH, Liu YF. TLR3 gene polymorphisms in cancer: a systematic review and meta-analysis. Chin J Cancer. 2015;34:272–284.
   PubMedGoogle Scholar
• de Oliveira RTG, Cordeiro JVA, Vitoriano BF, et al. ERVs-TLR3-IRF axis is linked to myelodysplastic syndrome pathogenesis. Med Oncol. 2021;38:27.
   PubMed Web of Science ®Google Scholar
• Mu Y, Chen Y, Zhang G, et al. Identification of stromal differentially expressed proteins in the colon carcinoma by quantitative proteomics. Electrophoresis. 2013;34:1679–1692.
   PubMed Web of Science ®Google Scholar
• Morimura S, Suzuki K, Takahashi K. Nonmuscle myosin IIA is required for lamellipodia formation through binding to WAVE2 and phosphatidylinositol 3,4,5-triphosphate. Biochem Biophys Res Commun 2011;404:834–840.
   PubMed Web of Science ®Google Scholar
• Park S-Y, Kim H, Yoon S, et al. KITENIN-targeting microRNA-124 suppresses colorectal cancer cell motility and tumorigenesis. Mol Ther. 2014;22:1653–1664.
   PubMed Web of Science ®Google Scholar
• Ravid K. MAL: not just a leukemia inducer. Blood. 2009;114:3977–3978.
   PubMed Web of Science ®Google Scholar
• Yu M, Wang J, Zhu Z, et al. Prognostic impact of MYH9 expression on patients with acute myeloid leukemia. Oncotarget. 2017;8:156–163.
   PubMedGoogle Scholar
• Veiga RN, de Oliveira JC, Gradia DF. PBX1: a key character of the hallmarks of cancer. J Mol Med (Berl). 2021;99:1667–1680.
   PubMed Web of Science ®Google Scholar
• Shimabe M, Goyama S, Watanabe-Okochi N, et al. Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene. 2009;28:4364–4374.
   PubMed Web of Science ®Google Scholar
• van der Meer LT, Jansen JH, van der Reijden BA. Gfi1 and Gfi1b: key regulators of hematopoiesis. Leukemia. 2010;24:1834–1843.
   PubMed Web of Science ®Google Scholar
• Botezatu L, Michel LC, Makishima H, et al. GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome. Exp Hematol 2016;44:590–5.e1.
   PubMed Web of Science ®Google Scholar
• Khandanpour C, Thiede C, Valk PJM, et al. A variant allele of growth factor independence 1 (GFI1) is associated with acute myeloid leukemia. Blood. 2010;115:2462–2472.
   PubMed Web of Science ®Google Scholar
• Petrusca DN, Toscani D, Wang F-M, et al. Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis. J Hematol Oncol. 2018;11:123. doi:10.3389/fonc.2019.00210.
   PubMed Web of Science ®Google Scholar
• Jagtap P, Szabó C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discovery. 2005;4:421–440.
   PubMed Web of Science ®Google Scholar
• Kontandreopoulou C-N, Diamantopoulos PT, Tiblalexi D, et al. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2021;5:4794–4805.
   PubMed Web of Science ®Google Scholar